Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

St. Louis, Missouri 63110


The durability of endovascular aneurysm repair (EVAR) has been limited by development of endoleaks which may be secondary to progressive aortic degeneration by matrix metalloproteases (MMP). Doxycycline is a known inhibitor of the MMP family of enzymes in aneurysms. The investigators propose a randomized, controlled trial of adjuvant doxycycline therapy with EVAR to determine its effects on re-intervention, aneurysm shrinkage and serum markers of aneurysmal degeneration.

Study summary:

Patients will be consented and enrolled at the time of their clinic visit or admission to the hospital for a planned EVAR, in accordance with institutional review board guidelines. Demographic, risk factor and medication regimen data will be obtained from the patient's clinical chart. Patients will be randomized to doxycycline therapy (100 mg taken twice daily) or a placebo. The patients will receive their first dose of study medication on the day following surgery, and continue the study therapy for 6 months. Plasma and serum will be obtained at the time of enrollment (baseline), and at each post-operative follow-up visit during the study as outlined above. Aliquots will be stored at -80ºC until assayed. Measurements of the circulating markers will be performed by commercially available assays for plasma MMP-9 (R&D Systems, Minneapolis, MN), serum IL-6 (R&D Systems) , IL-8 (R&D Systems), IFN-gamma (R&D Systems), and CRP (Bio-Check, Burlingame, CA) Data will be collected from the pre-operative and all post-operative CT scans regarding maximal aneurysm diameter and transverse neck diameter at 5 mm, 10 mm and 15 mm below the takeoff of the lowest renal artery. All documented endoleaks and their clinical type will be recorded, as will any re-intervention related to the graft or aneurysm. The primary end-points of the study related to aneurysm measurements will be an increase or decrease in any of the diameter measurements of the aorta by 2 mm or more on 2 consecutive CT scans or a change of 5 mm or more on any single scan. Of the circulating markers, an additional primary endpoint will be a 50% reduction in baseline MMP-9 after endografting. Secondary endpoints will be significant reductions over baseline in circulating IL-6, IL-8, IFN-γ, and CRP. An a priori power analysis indicates that at 6 months, reductions in circulating levels of these markers by 50% can be detected with a β-error of less than 0.1 and α-error of less than 0.05.


Inclusion Criteria: - Presence of an abdominal aortic aneurysm (AAA) with a maximum diameter of > or = 4.5 cm - Planned aneurysm exclusion with endoluminal stent graft (any brand) Exclusion Criteria: - Known malignancy not to include prostate cancer or any history of cancer that has not had a recurrence in the last 5 years. - Hypersensitivity to doxycycline or any of its components - Pregnancy - Ruptured AAA - Extension of covered portion of the graft above the renal arteries - Previous endoluminal aneurysm repair

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Adjunctive Treatment With Doxycycline to Enhance the Durability of Endovascular Aortic Aneurysm Repair

Official Title:

Adjunctive Treatment With Doxycycline in Endovascular Aneurysm Repair

Overall Status:


Study Phase:




Minimum Age:

50 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Barnes-Jewish Hospital Foundation

Oversight Authority:

United States: Institutional Review Board

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:

Overall Contact Information

Official Name:John A Curci, MD
Principal Investigator
Washington University School of Medicine

Study Dates

Start Date:March 2004
Completion Date:July 2006
Verification Date:September 2006
Last Changed Date:March 3, 2010
First Received Date:August 2, 2005

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Significant reductions at 6 months in serum C-reactive protein
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Significant reductions at 6 months in serum interferon-gamma
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Significant reductions at 6 months in serum IL-8
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Significant reductions at 6 months in serum interleukin-6 (IL-6)
Safety Issues:False
Outcome Type:Primary Outcome
Measure:50% reduction in baseline plasma MMP-9 at 6 months
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Change in aortic measurement by > 5 mm on a single scan
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Change in aortic measurements by > 2 mm on 2 consecutive scans
Safety Issues:False

Study Interventions

Intervention Type:Drug

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Barnes-Jewish Hospital Foundation

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Results Reference
Citation:Hackmann AE, Rubin BG, Sanchez LA, Geraghty PA, Thompson RW, Curci JA. A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J Vasc Surg. 2008 Sep;48(3):519-26; discussion 526. Epub 2008 Jul 15.

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.